FDA restricts Sarepta's gene therapy Elevidys after Duchenne patient deaths

14th November 2025 Uncategorised 0

The updated label now includes a boxed warning and a new “limitation of use” in addition to the removal of the prior indication for non-ambulatory patients with Duchenne muscular dystrophy.

More: FDA restricts Sarepta's gene therapy Elevidys after Duchenne patient deaths
Source: fierce